As DGAT2 plays a critical role in the generation of TGs and high levels of TG are associated with several negative clinical outcomes, e.g., insulin resistance, hyperlipidemia, and fatty liver disease, the rationale was to block TG synthesis via pharmacologic modulation (lowering) of DGAT2 activity. The gene discussed is DGAT2; the disease is hyperlipidemia.